- Home
- NNN vs MDGL Comparison
NNN vs MDGL Comparison
Compare NNN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNN
- MDGL
- Stock Information
- Founded
- NNN 1984
- MDGL 2011
- Country
- NNN United States
- MDGL United States
- Employees
- NNN N/A
- MDGL N/A
- Industry
- NNN Real Estate Investment Trusts
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- NNN Real Estate
- MDGL Health Care
- Exchange
- NNN Nasdaq
- MDGL Nasdaq
- Market Cap
- NNN 7.9B
- MDGL 6.8B
- IPO Year
- NNN N/A
- MDGL N/A
- Fundamental
- Price
- NNN $41.73
- MDGL $275.26
- Analyst Decision
- NNN Hold
- MDGL Strong Buy
- Analyst Count
- NNN 11
- MDGL 10
- Target Price
- NNN $44.60
- MDGL $420.63
- AVG Volume (30 Days)
- NNN 984.7K
- MDGL 335.5K
- Earning Date
- NNN 05-01-2025
- MDGL 05-01-2025
- Dividend Yield
- NNN 5.56%
- MDGL N/A
- EPS Growth
- NNN N/A
- MDGL N/A
- EPS
- NNN 2.14
- MDGL N/A
- Revenue
- NNN $884,713,000.00
- MDGL $317,383,000.00
- Revenue This Year
- NNN $4.43
- MDGL $285.43
- Revenue Next Year
- NNN $4.26
- MDGL $63.77
- P/E Ratio
- NNN $19.52
- MDGL N/A
- Revenue Growth
- NNN 5.40
- MDGL N/A
- 52 Week Low
- NNN $35.80
- MDGL $200.63
- 52 Week High
- NNN $49.57
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- NNN 53.34
- MDGL 38.56
- Support Level
- NNN $41.00
- MDGL $265.39
- Resistance Level
- NNN $41.94
- MDGL $275.54
- Average True Range (ATR)
- NNN 0.64
- MDGL 11.39
- MACD
- NNN -0.00
- MDGL -1.08
- Stochastic Oscillator
- NNN 77.27
- MDGL 24.12
About NNN NNN REIT Inc.
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue. The maximum of the company's properties are located in the South and Southeast of the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.